المصدر: A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The Anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06166472Test

المصدر: A Randomized, Double-blind, Phase III Trial to Compare the Efficacy and Safety of AK104 Combined With Chemotherapy to Tislelizumab Combined With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer (NSCLC)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05990127Test

المصدر: A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK112 in Patients With Advanced Malignant Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05951608Test

المصدر: A Phase Ib/II Clinical Trial of AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05904379Test

المصدر: A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05868876Test

المصدر: A Randomized, Controlled, Multi-center Phase III Clinical Study of AK112 Combined With Chemotherapy Versus PD-1 Inhibitor Combined With Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05840016Test

المصدر: A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AK130 (TIGIT/TGF-β Bifunctional Fusion Protein) in Patients With Advanced Malignant Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05653284Test

المصدر: A Phase Ia/Ib, Open Label, Dose Escalation and Dose Extension Trial of Anti-PD-1 and LAG-3 Bispecific Antibody AK129 to Evaluate the Safety, Tolerability and Antitumor Efficacy in Patients With Advanced Malignant Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05645276Test

المصدر: A Randomized Controlled, Multi-center Phase III Clinical Trial of AK112 Versus Pembrolizumab as First-line Treatment for PD-L1-Positive Locally-Advanced or Metastatic Non-Small Cell Lung Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05499390Test

المصدر: A Phase I Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 Monotherapy in Patients With Advanced Malignant Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05393063Test